From GlobeNewswire: 2025-05-20 13:00:00

The atopic dermatitis market is growing due to increased prevalence and awareness, driving demand for advanced treatments. Breakthroughs in biologics, small molecules, and personalized medicine are reshaping the therapeutic landscape, with a robust pipeline and frequent drug approvals. Key companies like Jiangsu Vcare Pharmaceutical and Nektar Therapeutics are developing promising therapies.

Innovations in pediatric care and improved global access are expanding opportunities in the evolving moderate to severe atopic dermatitis space. DelveInsight’s report highlights 45+ companies working on 50+ pipeline drugs. Promising therapies like VC005, TQH2722, and Rezpegaldesleukin are in clinical trials, showing positive results.

Kymera Therapeutics has initiated a Phase Ib trial for KT-621, a degrader of STAT6, in atopic dermatitis patients. Corvus Pharmaceuticals will present soquelitinib data at a dermatology conference. Additionally, rezpegaldesleukin received fast-track designation from the FDA for moderate-to-severe atopic dermatitis treatment.

Atopic dermatitis, a chronic inflammatory skin condition, affects individuals of all ages. It is often accompanied by other allergic conditions like asthma and allergic rhinitis. Symptoms range from dry skin to intense itching, with severe cases causing discomfort and impacting daily life. Treatment involves skincare, medications, and lifestyle adjustments.

Managing atopic dermatitis requires personalized strategies like trigger identification, skincare routines, and anti-inflammatory therapies. Biologics such as dupilumab and crisaborole offer significant benefits. Dilute bleach baths and probiotics may also help. The report offers insights into the emerging therapies for moderate to severe atopic dermatitis.

DelveInsight’s pipeline report provides a comprehensive view of emerging atopic dermatitis treatments by product type, clinical stages, and mechanism of action. Key companies like Jiangsu Vcare Pharmaceutical and Nektar Therapeutics are at the forefront of developing innovative therapies for atopic dermatitis. The report also covers market drivers, barriers, and opportunities in this space.



Read more at GlobeNewswire: Moderate to Severe Atopic Dermatitis Clinical Trial